These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9330023

  • 1. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
    Monteleone P, Catapano F, Di Martino S, Ferraro C, Maj M.
    Br J Psychiatry; 1997 Jun; 170():554-7. PubMed ID: 9330023
    [Abstract] [Full Text] [Related]

  • 2. Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.
    Monteleone P, Catapano F, Bortolotti F, Maj M.
    Biol Psychiatry; 1997 Aug 01; 42(3):175-80. PubMed ID: 9232209
    [Abstract] [Full Text] [Related]

  • 3. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar 01; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 4. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
    Marazziti D, Pfanner C, Palego L, Gemignani A, Milanfranchi A, Ravagli S, Lensi P, Presta S, Cassano GB.
    Pharmacopsychiatry; 1997 Nov 01; 30(6):245-9. PubMed ID: 9442546
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.
    J Clin Psychiatry; 2003 Jun 01; 64(6):640-7. PubMed ID: 12823077
    [Abstract] [Full Text] [Related]

  • 6. Fenfluramine challenge test in obsessive-compulsive disorder--first results.
    Pidrman V, Tůma I.
    Acta Medica (Hradec Kralove); 1997 Jun 01; 40(4):99-102. PubMed ID: 9481883
    [Abstract] [Full Text] [Related]

  • 7. Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa.
    Monteleone P, Brambilla F, Bortolotti F, La Rocca A, Maj M.
    Br J Psychiatry; 1998 May 01; 172():439-42. PubMed ID: 9747408
    [Abstract] [Full Text] [Related]

  • 8. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S.
    Psychiatry Clin Neurosci; 2023 Sep 01; 77(9):478-485. PubMed ID: 37169515
    [Abstract] [Full Text] [Related]

  • 9. Comparing the Effects of a Herbal Drug based on Echium Amoenum With Fluvoxamine in the Treatment of Adolescents with Obsessive-compulsive Disorder.
    Noras MR, Soltanifar A, Salari R, Jarahi L, Abrishami MH.
    Curr Drug Discov Technol; 2022 Sep 01; 19(5):e240622206368. PubMed ID: 35748547
    [Abstract] [Full Text] [Related]

  • 10. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder.
    Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG.
    Psychiatry Res; 1992 Apr 01; 42(1):81-92. PubMed ID: 1603884
    [Abstract] [Full Text] [Related]

  • 11. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.
    Am J Psychiatry; 1999 Sep 01; 156(9):1409-16. PubMed ID: 10484953
    [Abstract] [Full Text] [Related]

  • 12. Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine.
    Fineberg NA, Roberts A, Montgomery SA, Cowen PJ.
    Br J Psychiatry; 1997 Sep 01; 171():280-2. PubMed ID: 9337985
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH.
    J Clin Psychopharmacol; 1993 Oct 01; 13(5):354-8. PubMed ID: 8227493
    [Abstract] [Full Text] [Related]

  • 14. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK, Kozak MJ, Liebowitz M, White KL.
    Int Clin Psychopharmacol; 1996 Mar 01; 11(1):21-9. PubMed ID: 8732310
    [Abstract] [Full Text] [Related]

  • 15. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.
    Arch Gen Psychiatry; 1994 Apr 01; 51(4):302-8. PubMed ID: 8161290
    [Abstract] [Full Text] [Related]

  • 16. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
    Peter H, Tabrizian S, Hand I.
    Int J Psychiatry Med; 2000 Apr 01; 30(1):27-39. PubMed ID: 10900559
    [Abstract] [Full Text] [Related]

  • 17. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S.
    Int Clin Psychopharmacol; 2014 Nov 01; 29(6):344-50. PubMed ID: 24850229
    [Abstract] [Full Text] [Related]

  • 18. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT.
    J Am Acad Child Adolesc Psychiatry; 2001 Feb 01; 40(2):222-9. PubMed ID: 11211371
    [Abstract] [Full Text] [Related]

  • 19. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hollander E, Kaplan A, Schmeidler J, Yang H, Li D, Koran LM, Barbato LM.
    J Neuropsychiatry Clin Neurosci; 2005 Feb 01; 17(4):472-7. PubMed ID: 16387985
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M, Pini S, Bellantuono C, Wilkinson G.
    Br J Psychiatry; 1995 Apr 01; 166(4):424-43. PubMed ID: 7795913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.